table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 outpatients
potential COVID-19 treatments
adjuvant therapies
febuxostat Davoodi
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
colchicine PRINCIPLE ... COLCORONA
corticosteroids
ciclesonide Clemency Ezer N ...
Immunostimulants drugs
convalescent plasma treatment CONV-ERT C3PO CoV-Early ...
Early convalescent plasma. CoV-Early ...
interferon
inhaled interferon
SNG001 inhaled interferon beta ACTIV-2 SNG001
peginterferon TOGETHER interferon lambda Feld
neutralizing antibody
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) ACTIV-2 ...
bamlanivimab monotherapy OPTIMISE-C19 ... BLAZE-1 phase 2 ...
bamlanivimab/etesevimab BLAZE-1 phase 2 ... BLAZE-1 phase 3 ... BLAZE-4 OPTIMISE-C19 ...
Bebtelovimab (LY-CoV1404) BLAZE 4 LY-CoV1404
casirivimab/imdevimab (Ronapreve) Cov-2067 Weinreich ... Cov-2069 ... Mazzotta
cilgavimab and tixagevimab (Evusheld) TACKLE
regdanvimab (Regkirona- CT-P59-Celltrion) CT-P59 3.2 part 1 CT-P59 3.2 part 2
sotrovimab (Xevudy; VIR-7831) COMET-ICE
inhaled corticosteroids
budesonide PRINCIPLE STOIC
antiandrogenic
dutasteride Cadegiani ...
antiviral and associated therapy
azithromycin ACTION PRINCIPLE Hinks ...
chloroquine and derivatives ALBERTA HOPE-Covid19
hydroxychloroquine NCT04597775 COPE – Coalition V COVID-PEP Severity ... BCN PEP-CoV-2-Study 2 ... PATCH Cohort 1 ... Reis ... Q-PROTECT -HCQ alone COMIHY
fluvoxamine COVID-OUT ... Lenze ... TOGETHER ACTIV-6
hydroxychloroquine plus macrolides NCT04621461
azithromycin plus hydroxychloroquine Q-PROTECT -AZI ... Rodrigues Q-PROTECT ...
ivermectin ACTIV-6 ... IVERCORCOVID19 ... Chaccour ACTIV 6 ivermectin Buonfrate ... Chahla COVID-OUT ... Lopez-Medina TOGETHER ... Podder
ivermectin plus doxycycline Chowdhury A
lopinavir/ritonavir Reis ...
molnupiravir MOVe-OUT Fischer ...
nirmatrelvir / ritonavir (Paxlovid) EPIC-HR
nitazoxanide RM08-3008 ...
remdesivir PINETREE ...
sofosbuvir and daclatasvir Roozbeh
umifenovir (arbidol) Ramachandran
zinc Thomas ...
Oral antidiabetic drugs
metformin TOGETHER COVID-OUT ...
Renin-angiotensin-system-acting agents
angiotensin receptor blockers (ARBs) University of Minnesota
discontinuation of ACEI/ARB ACEI-COVID ...
Vitamins
vitamin C Thomas ...
zinc plus vitamin c Thomas ...

60 studies excluded by filtering options 1

5092 Yang, 2020 1133not a RCThigh risk of bias
5228 Bean, 2020 1193not a RCThigh risk of bias
5295 Zhang, 2020 1133not a RCThigh risk of bias
5331 Li, 2020 1134not a RCThigh risk of bias
5332 Meng, 2020 1134not a RCThigh risk of bias
5345 Yan et al., 2020 1204not a RCThigh risk of bias
5346 Mancia, 2020 1203not a RCThigh risk of bias
5347 Mehra, 2020 2124excludednot a RCThigh risk of bias
5348 Reynolds (COVID positive patient), 2020 1133not a RCThigh risk of bias
5349 Reynolds (prophylaxis), 2020 1133not a RCThigh risk of bias
5370 Khera (outpatients), 2020 1133not a RCThigh risk of bias
5372 Khera (inpatients), 2020 1133not a RCThigh risk of bias
5399 Northwell Consortium (Richardson), 2020 0990selection pending
5440 Morales, 2020 1130not a RCTrisk of bias not avaialble
5604 Schneeweiss, 0 0130selection pending
5605 Vila-Corcole, 0 0130selection pending
5619 Pan, 2020 0130selection pending
5797 Rossi, 0 0130selection pending
5903 Anzola, 2020 0100selection pending
6660 Bae, 2021 0120selection pending
6729 Shah, 2021 1133not a RCThigh risk of bias
6788 Waissengrin, 2021 0130selection pending
6790 Pawlowski, 2021 1130not a RCTrisk of bias not avaialble
6894 Andrejko, 2021 1200not a RCTrisk of bias not avaialble
6927 Rossman, 2021 0130selection pending
6931 Yair, 2921 1320not a RCTrisk of bias not avaialble
6934 Boyarsky, 2021 1320not a RCTrisk of bias not avaialble
6949 Pawlowski, 2021 1130not a RCTrisk of bias not avaialble
6981 Public Health England (Harris), 2021 1133not a RCThigh risk of bias
7025 Haberman, 2021 0130selection pending
7070 PHE variants (Technical briefing 12 22 may 2021), 2021 2202excludednot a RCT
7325 Skowronski, 2021 0130selection pending
7419 Scotland delta (Sheikh), 2021 1203not a RCThigh risk of bias
7420 PHE (Stowe), 2021 2133excludednot a RCThigh risk of bias
7950 Harris, 2021 1133not a RCThigh risk of bias
8143 Butt, 2021 1202not a RCT
8147 Canada (Nasreen), 2021 1202not a RCT
8149 PHE Technical briefing 16 (11/18 June 2021), 2021 2133excludednot a RCThigh risk of bias
8150 Ramasamy, 2021 0320selection pending
8164 Public Health England, May 16, 2021 (Bernal), 2021 1202not a RCT
8255 REACT-SCOT, 2021 1200not a RCTrisk of bias not avaialble
8272 Martinez-Baz, 2021 1130not a RCTrisk of bias not avaialble
8274 REACT-1 round 13 final report (Elliott, Imperial College London), 2021 1133not a RCThigh risk of bias
8275 Musser, 2021 2130excludednot a RCTrisk of bias not avaialble
8294 CDC Mesa County, Colorado, 2021 1133not a RCThigh risk of bias
8313 Bahl (Fully vaccinated vs unvaccinated), 2021 0100selection pending
8350 Rosenberg, 2021 2130excludednot a RCTrisk of bias not avaialble
8359 Oxford (Pouwels), 2021 1132not a RCT
8360 HEROES-RECOVER (Fowlkes), 2021 1133not a RCThigh risk of bias
8513 Grannis, 2021 1203not a RCThigh risk of bias
8514 VA (Bajema), 2021 1203not a RCThigh risk of bias
8515 Scobie, 2021 2200excludednot a RCTrisk of bias not avaialble
9170 UKHSA report 33 (23 december 2021), 2021 2200excludednot a RCTrisk of bias not avaialble
9176 UKHSA 31 december 2021, 2021 2200excludednot a RCTrisk of bias not avaialble
9214 Southern California (Lewnard), 2022 2130excludednot a RCTrisk of bias not avaialble
9216 Sultan, 2022 0120selection pending
9267 Ostropolets, 2021 0120selection pending
9294 UKHSA (report W4- 27 January), 2022 2120excludednot a RCTrisk of bias not avaialble
9491 Li X, 2022 1120not a RCTrisk of bias not avaialble
9590 UKHSA report week 12 (24 March 2022), 2022 1120not a RCTrisk of bias not avaialble

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons